Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.
Chevalier
N
N
Solari
M L
ML
Becker
H
H
Pantic
M
M
Gärtner
F
F
Maul-Pavicic
A
A
Hübner
J
J
Wäsch
R
R
Schmitt-Gräff
A
A
Lübbert
M
M
D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects*; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D000069439:Dasatinib; D005434:Flow Cytometry; D006098:Granulocytes / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology* / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D015996:Survival Rate; D013844:Thiazoles / Q000627:therapeutic use*; D014178:Translocation, Genetic; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib